Pulmonx Corporation: Company Profile and Recent Activity

Introduction

Pulmonx Corporation (ticker: LUNG) is a privately held medical device company based in Redwood City, California, and has an additional office in Neuchâtel, Switzerland. The company was established to address severe chronic obstructive pulmonary disease (COPD) and emphysema by developing minimally invasive bronchoscopic treatments, notably the Zephyr® Endobronchial Valve. In June 2018, the U.S. Food and Drug Administration granted the Zephyr Valve breakthrough designation and approved it as a non-surgical option for lung volume reduction.

Corporate Structure and Workforce

According to its LinkedIn profile, Pulmonx has a workforce of between 201 and 500 employees in various departments, including research and development, clinical affairs, regulatory, sales and marketing, and corporate services. The company is an equal opportunity employer that emphasizes diversity. Its management team and board include individuals with expertise in interventional pulmonology, medical technology commercialization, and nonprofit leadership.

Zephyr Valve by Pawel Czerwinski

Developments and News

• On May 23, 2025, Pulmonx filed a Form 8-K (Item 5.07) with the Securities and Exchange Commission. The publicly available information from that filing did not include financial metrics or details on material events.
• On May 30, 2025, the company submitted a Specialized Disclosure Report (Form SD) regarding conflict minerals, confirming that its Chartis® Console contains tin and gold. The report describes steps taken to obtain country-of-origin information from suppliers under SEC Rule 13p-1.
• On July 30, 2025, Pulmonx filed another Form 8-K (Item 2.02) that also did not provide specific revenue or earnings data in the publicly accessible section.
• In a July 2025 LinkedIn post, Pulmonx noted findings suggesting that low-dose CT screening identifies emphysema in nearly one-third of participants originally screened for lung cancer. The company indicated that earlier detection could facilitate access to bronchoscopic lung volume reduction with Zephyr Valves.

Financial and Strategic Analysis

As of July 31, 2025, shares of Pulmonx traded on the NASDAQ under the ticker LUNG at a price of $1.99 per share, reflecting a 36.83% decline over the recent trading period, with an average daily trading volume of 483,242 shares. The decline may reflect investor concerns regarding the timing of clinical data releases and broader market conditions affecting the medical device sector.

In terms of strategy, Pulmonx is focused on enhancing its clinical evidence base. More than 100 peer-reviewed articles support the safety and efficacy of the Zephyr Valve. Additionally, complementary tools, including the StratX® quantitative CT analysis and the Chartis pulmonary assessment system, facilitate precise patient selection for the procedure. The company operates globally, with a presence in the United States, Europe, Australia, Asia, and Latin America, and offers educational programs for healthcare professionals.

Market Position and Industry Context

COPD affected an estimated 175 million people globally as of 2015 and was the third leading cause of death in the United States, where approximately 16 million adults were diagnosed with the disease. Emphysema, a progressive ailment characterized by irreversible lung-tissue destruction, affected roughly 3.8 million Americans in 2018, with about 1.5 million considered to have severe disease. Traditional surgical options for lung volume reduction involve significant risks, creating a demand for less invasive therapies like the Zephyr Valve. This treatment has been included in guidelines from the Global Initiative for Chronic Obstructive Lung Disease and the U.K. National Institute for Health and Care Excellence, indicating its recognition as a viable treatment option for eligible patients.

tl;dr

Pulmonx’s stock closed at $1.99 on July 31, 2025, reflecting a 36.83% decline amid limited financial disclosures in recent SEC filings on May 23 and July 30. The company’s Form SD (filed May 30) outlined its compliance with conflict minerals regulation. In July 2025, Pulmonx highlighted findings that low-dose CT scans detected emphysema in approximately one-third of lung cancer screening participants, suggesting an opportunity for early intervention using Zephyr® Endobronchial Valves. Future updates on clinical trial data and financial performance will be important for evaluating Pulmonx’s outlook.